Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorRUSSO, Momtchilo
dc.contributor.authorMENDES-CORREA, Maria Cassia
dc.contributor.authorLINS, Bruna B.
dc.contributor.authorKERSTEN, Victor
dc.contributor.authorPERNAMBUCO, Paulo C. A.
dc.contributor.authorMARTINS, Toni Ricardo
dc.contributor.authorTOZETTO-MENDOZA, Tania Regina
dc.contributor.authorBOAS, Lucy Santos Vilas
dc.contributor.authorGOMES, Brisa Moreira
dc.contributor.authorDATI, Livia Mendonca Munhoz
dc.contributor.authorDUARTE-NETO, Amaro Nunes
dc.contributor.authorREIGADO, Gustavo Roncoli
dc.contributor.authorFREDERICO, Ana Beatriz T.
dc.contributor.authorCUNHA, Danielle R. de A.
dc.contributor.authorPAULA, Anderson Vicente de
dc.contributor.authorSILVA, Jose Igor G. da
dc.contributor.authorVASCONCELOS, Carlos F. Moreira
dc.contributor.authorCHAMBERGO, Felipe S.
dc.contributor.authorNUNES, Viviane Abreu
dc.contributor.authorBOM, Ana Paula Dinis Ano
dc.contributor.authorCASTILHO, Leda R.
dc.contributor.authorMARTINS, Rodrigo A. P.
dc.contributor.authorHIRATA, Mario Hiroyuki
dc.contributor.authorMIROTTI, Luciana
dc.contributor.authorTRIPP, Ralph A.
dc.date.accessioned2024-02-15T14:47:49Z
dc.date.available2024-02-15T14:47:49Z
dc.date.issued2023
dc.description.abstractMucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as an adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight loss and mortality indicators. However, when compared with subcutaneous administration, the intranasal route was more effective in the pulmonary clearance of the virus and induced higher neutralizing antibodies and anti-S IgA titers. In addition, the intranasal vaccination afforded protection against gamma, delta, and omicron virus variants of concern. Furthermore, the intranasal vaccine formulation was superior to intramuscular vaccination with a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein (Oxford/AstraZeneca) in terms of virus lung clearance and production of neutralizing antibodies in serum and bronchial alveolar lavage (BAL). Finally, the intranasal liposomal formulation boosted heterologous immunity induced by previous intramuscular vaccination with the Oxford/AstraZeneca vaccine, which was more robust than homologous immunity.eng
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.description.sponsorshipPrograma Inova Fiocruz [INOVA VPPCB-005-FIO-20-2-54]
dc.description.sponsorshipVerba parlamentar Davi Miranda [39540021]
dc.description.sponsorshipPIPAE-USP-2021 [2021.1.10424.1.9]
dc.description.sponsorshipFundaco de AmparoaPesquisa do Estado do Rio de Janeiro (FAPERJ) [E-26/211.711/2021]
dc.description.sponsorshipInternational Retinal Research Foundation/2021
dc.description.sponsorshipGrant Fundaco de Amparo a Pesquisa do Estadode So Paulo (FAPESP) [2021/12502-7]
dc.identifier.citationVACCINES, v.11, n.11, article ID 1732, 17p, 2023
dc.identifier.doi10.3390/vaccines11111732
dc.identifier.eissn2076-393X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/57956
dc.language.isoeng
dc.publisherMDPIeng
dc.relation.ispartofVaccines
dc.rightsopenAccesseng
dc.rights.holderCopyright MDPIeng
dc.subjectSARS-CoV-2eng
dc.subjectvaccineeng
dc.subjecthACE2 transgenic miceeng
dc.subjectintranasal routeeng
dc.subjectspike proteineng
dc.subjectcationic liposomeeng
dc.subjectCpG-ODNseng
dc.subjectheterologous immunityeng
dc.subject.wosImmunologyeng
dc.subject.wosMedicine, Research & Experimentaleng
dc.titleIntranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infectioneng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalRUSSO, Momtchilo:Univ Sao Paulo ICB USP, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, Brazil
hcfmusp.author.externalLINS, Bruna B.:Univ Sao Paulo ICB USP, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, Brazil
hcfmusp.author.externalKERSTEN, Victor:Univ Sao Paulo ICB USP, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, Brazil
hcfmusp.author.externalPERNAMBUCO, Paulo C. A.:Univ Sao Paulo ICB USP, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, Brazil
hcfmusp.author.externalGOMES, Brisa Moreira:Univ Sao Paulo ICB USP, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, Brazil
hcfmusp.author.externalDATI, Livia Mendonca Munhoz:Fac Ciencias Farmaceut Univ Sao Paulo FCF USP, Dept Anal Clin & Toxicol, BR-05508000 Sao Paulo, Brazil
hcfmusp.author.externalREIGADO, Gustavo Roncoli:Escola Artes Ciencias & Humanidades Univ Sao Paulo, Lab Biotecnol, BR-03828000 Sao Paulo, Brazil
hcfmusp.author.externalFREDERICO, Ana Beatriz T.:Oswaldo Cruz Fdn Fiocruz, Inst Technol Immunobiol Bio Manguinhos, Immunol Technol Lab, BR-21040900 Rio de Janeiro, Brazil
hcfmusp.author.externalCUNHA, Danielle R. de A.:Oswaldo Cruz Fdn Fiocruz, Inst Technol Immunobiol Bio Manguinhos, Immunol Technol Lab, BR-21040900 Rio de Janeiro, Brazil
hcfmusp.author.externalPAULA, Anderson Vicente de:Fac Med Univ Sao Paulo FM USP, Lab Virol LIM52, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil
hcfmusp.author.externalSILVA, Jose Igor G. da:Univ Fed Rio de Janeiro UFRJ, Inst Ciencias Biomed, Programa Biol Celular & Desenvolvimento, BR-21941902 Rio de Janeiro, Brazil
hcfmusp.author.externalVASCONCELOS, Carlos F. Moreira:Univ Fed Rio de Janeiro UFRJ, Inst Ciencias Biomed, Programa Biol Celular & Desenvolvimento, BR-21941902 Rio de Janeiro, Brazil
hcfmusp.author.externalCHAMBERGO, Felipe S.:Escola Artes Ciencias & Humanidades Univ Sao Paulo, Lab Biotecnol, BR-03828000 Sao Paulo, Brazil
hcfmusp.author.externalNUNES, Viviane Abreu:Escola Artes Ciencias & Humanidades Univ Sao Paulo, Lab Biotecnol, BR-03828000 Sao Paulo, Brazil
hcfmusp.author.externalBOM, Ana Paula Dinis Ano:Oswaldo Cruz Fdn Fiocruz, Inst Technol Immunobiol Bio Manguinhos, Immunol Technol Lab, BR-21040900 Rio de Janeiro, Brazil
hcfmusp.author.externalCASTILHO, Leda R.:Fed Univ Rio de Janeiro UFRJ, COPPE, Cell Culture Engn Lab, BR-21941598 Rio de Janeiro, Brazil
hcfmusp.author.externalMARTINS, Rodrigo A. P.:Univ Fed Rio de Janeiro UFRJ, Inst Ciencias Biomed, Programa Biol Celular & Desenvolvimento, BR-21941902 Rio de Janeiro, Brazil
hcfmusp.author.externalHIRATA, Mario Hiroyuki:Fac Ciencias Farmaceut Univ Sao Paulo FCF USP, Dept Anal Clin & Toxicol, BR-05508000 Sao Paulo, Brazil
hcfmusp.author.externalMIROTTI, Luciana:Oswaldo Cruz Fdn Fiocruz, Inst Sci & Technol Biomodels ICTB, BR-21040900 Rio de Janeiro, Brazil
hcfmusp.citation.scopus1
hcfmusp.contributor.author-fmusphcMARIA CASSIA JACINTHO MENDES CORREA
hcfmusp.contributor.author-fmusphcTONI RICARDO MARTINS
hcfmusp.contributor.author-fmusphcTANIA REGINA TOZETTO MENDOZA
hcfmusp.contributor.author-fmusphcLUCY SANTOS VILAS BOAS
hcfmusp.contributor.author-fmusphcAMARO NUNES DUARTE NETO
hcfmusp.description.articlenumber1732
hcfmusp.description.issue11
hcfmusp.description.volume11
hcfmusp.origemWOS
hcfmusp.origem.pubmed38006064
hcfmusp.origem.scopus2-s2.0-85178292900
hcfmusp.origem.wosWOS:001113962900001
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAfkhami S, 2022, CELL, V185, P896, DOI 10.1016/j.cell.2022.02.005eng
hcfmusp.relation.referenceAlameh MG, 2021, IMMUNITY, V54, P2877, DOI 10.1016/j.immuni.2021.11.001eng
hcfmusp.relation.referenceAlberca-Custodio RW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00692eng
hcfmusp.relation.referenceAlvim RGF, 2022, BIOCHEM ENG J, V186, DOI 10.1016/j.bej.2022.108537eng
hcfmusp.relation.referenceBao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-yeng
hcfmusp.relation.referenceBoyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775eng
hcfmusp.relation.referenceBrandtzaeg P, 2009, SCAND J IMMUNOL, V70, P505, DOI 10.1111/j.1365-3083.2009.02319.xeng
hcfmusp.relation.referenceCastro JT, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-32547-yeng
hcfmusp.relation.referenceChu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029eng
hcfmusp.relation.referenceCollins FS, 2021, SCIENCE, V373, P165, DOI 10.1126/science.abj8547eng
hcfmusp.relation.referenceCorman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045eng
hcfmusp.relation.referenceDiallo BK, 2023, NPJ VACCINES, V8, DOI 10.1038/s41541-023-00665-3eng
hcfmusp.relation.referenceFirmino-Cruz L, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10081305eng
hcfmusp.relation.referenceHalfmann PJ, 2022, NATURE, V603, P687, DOI 10.1038/s41586-022-04441-6eng
hcfmusp.relation.referenceHand TW, 2021, ANNU REV IMMUNOL, V39, P695, DOI 10.1146/annurev-immunol-102119-074236eng
hcfmusp.relation.referenceHarder T, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.41.2100920eng
hcfmusp.relation.referenceHartmann G, 2003, EUR J IMMUNOL, V33, P1633, DOI 10.1002/eji.200323813eng
hcfmusp.relation.referenceHassan AO, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109452eng
hcfmusp.relation.referenceHosseini ES, 2020, VIROLOGY, V551, P1, DOI 10.1016/j.virol.2020.08.011eng
hcfmusp.relation.referenceIsraelow B, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abl4509eng
hcfmusp.relation.referenceLevin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583eng
hcfmusp.relation.referenceMcCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06eng
hcfmusp.relation.referenceMendes-Correa MC, 2023, VIRUSES-BASEL, V15, DOI 10.3390/v15061270eng
hcfmusp.relation.referenceMendrone A, 2021, TRANSFUSION, V61, P1181, DOI 10.1111/trf.16268eng
hcfmusp.relation.referenceMirotti LC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00047eng
hcfmusp.relation.referenceNurtop E, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1105-5eng
hcfmusp.relation.referenceOGRA PL, 1984, REV INFECT DIS, V6, pS361eng
hcfmusp.relation.referenceOu BS, 2023, bioRxiv, DOI [10.1101/2023.01.02.522505, 10.1101/2023.01.02.522505, DOI 10.1101/2023.01.02.522505]eng
hcfmusp.relation.referencePräbst K, 2017, METHODS MOL BIOL, V1601, P1, DOI 10.1007/978-1-4939-6960-9_1eng
hcfmusp.relation.referenceReigado GR, 2022, BIOTECHNOL APPL BIOC, V69, P2673, DOI 10.1002/bab.2314eng
hcfmusp.relation.referenceRivera-Hernandez T, 2020, MBIO, V11, DOI 10.1128/mBio.00122-20eng
hcfmusp.relation.referenceSee RH, 2006, J GEN VIROL, V87, P641, DOI 10.1099/vir.0.81579-0eng
hcfmusp.relation.referenceSengupta A, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10040504eng
hcfmusp.relation.referenceSlavov SN, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14102148eng
hcfmusp.relation.referenceSterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223eng
hcfmusp.relation.referenceSuzuki K, 2010, IMMUNITY, V33, P71, DOI 10.1016/j.immuni.2010.07.003eng
hcfmusp.relation.referenceVillas-Boas LS, 2022, CLINICS, V77, DOI 10.1016/j.clinsp.2022.100068eng
hcfmusp.relation.referenceVollmer J, 2004, EUR J IMMUNOL, V34, P251, DOI 10.1002/eji.200324032eng
hcfmusp.relation.referenceWang ZJ, 2022, J EXP MED, V219, DOI 10.1084/jem.20220826eng
hcfmusp.relation.referenceWendel S, 2020, TRANSFUSION, V60, P2938, DOI 10.1111/trf.16065eng
hcfmusp.relation.referenceWrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1126/science.abb2507, 10.1101/2020.02.11.944462]eng
hcfmusp.relation.referenceZhang GF, 2022, J MED VIROL, V94, P5678, DOI 10.1002/jmv.28032eng
hcfmusp.relation.referenceZhu Y, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/394578eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication4ec4044d-75d1-4d30-8176-efd04b22c8d6
relation.isAuthorOfPublication2eea350d-346b-463d-b40d-74641c031ccc
relation.isAuthorOfPublication34a7a0e8-8141-4d16-a9ec-7da8bb0b64d7
relation.isAuthorOfPublication722c72bc-bacb-4fa4-8a78-8d1b004a0a66
relation.isAuthorOfPublication01caf18a-6e85-42e6-9d58-52f78bf229b5
relation.isAuthorOfPublication.latestForDiscovery4ec4044d-75d1-4d30-8176-efd04b22c8d6
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_RUSSO_Intranasal_Liposomal_Formulation_of_Spike_Protein_Adjuvanted_with_2023.PDF
Tamanho:
2.33 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/05
Carregar mais